Metrics raised 3
- FY'28 revenue target set at ~₹1,500 crores and FY'28 EBITDA target at ~₹450 crores (previously referenced as a ₹1,500 crores topline target without specified timing or EBITDA; FY'27 EBITDA guidance of comfortably crossing ₹300 crores was reaffirmed)
- Corporate Learning steady-state target of ~30% EBITDA margin and ~12% organic growth (from Q1 reported 25.3% margin and 6.9% growth)
- Unbound Medicine margin trajectory set to mid-to-late-20s EBITDA (Rule of 40), then Rule of 50 (from current 18-20% EBITDA margin at ~$800K monthly run rate)
Event Participants
Executives
6 Christine Miranda, Prarthana Agarwal, Rahul Arora, Sanjeev Talwar, Soma Bhaduri, Sukhwant Singh
Analysts
7 Kashish Mehta, Kaushik Jhawar, Krushi Parekh, Mahesh BP, Nachiket Kale, Ravi Kumar Naredi, Vikas Mhatre
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹224.24 crores | Up 20.4% YoY; strongest Q1 in company history; headcount grew <3%, driving operating leverage |
| Ex-AJE Revenue | ₹198.47 crores | Up 28.4% YoY, as AJE resets by design; underlying business grew faster than reported |
| Segment: Research Solutions | ₹123.23 crores | Up 13.2% YoY; 55% of total revenue; EBITDA +37.9%; segment margin 45.1%; core ex-AJE grew 26.3% |
| Segment: Education Solutions | ₹73.41 crores | Up 42.2% YoY and 22.1% QoQ; margin 35.1%; includes first full quarter of Unbound Medicine |
| Segment: Corporate Learning (Liberate) | ₹27.60 crores | Up 6.9% YoY; second consecutive growth quarter; EBITDA +60.7%; margin 25.3% vs 16.9% a year ago |
| EBITDA | ₹76.96 crores | Up 53.0% YoY; ex-AJE EBITDA up 50.5% |
| EBITDA Margin | 34.3% | Expanded from 27.0% YoY; ex-AJE margin 32.4%, up close to 5 points |
| Profit After Tax | ₹50.39 crores | Up 43.0% YoY; no exceptional items in the quarter |
| Basic EPS | ₹29.70 | All-time Q1 high, up from ₹20.78 YoY |
| Cash & Cash Equivalents | ₹138.02 crores | As of 30 June 2026; borrowings of ₹37.63 crores relate to the Unbound Medicine acquisition facility |
| DSO | 45 days | Improved from 51 days at end of March; collections described as tight |
| Client Count | 841 | Up from 404 a year ago on Unbound institutional subscribers; down from 906 QoQ due solely to AJE pruning |
Geographic & Segment Commentary
Research Solutions: Segment revenue of ₹123.23 crores, up 13.2% YoY with EBITDA up 37.9% and margin at 45.1%, as AI-enabled production moved from pilot to core delivery. DigiCore (AI-enabled production ecosystem) and Research Integrity Check (paper mill, identity fraud, image manipulation detection) are live in client delivery; platform stack (HighWire, DigiCore Pro, THINK365) runs mission-critical workflows on multi-year contracts. AJE is resetting by design after pruning — revenue deliberately smaller but higher quality; launched Pre-Submission Peer Review in April with demand ahead of plan; controlled-work manuscript acceptance rate of ~52% vs industry baseline of ~32%. MPS is now the second-largest peer-review provider by volume and aims to be first by end of 2026.
Education Solutions: Revenue up 42.2% YoY to ₹73.41 crores and 22.1% QoQ at a 35.1% EBITDA margin, driven by Unbound Medicine's first full quarter and organic compounding. AI-enabled content and production work with largest U.S. K-12 and higher-education organizations moved from pilots into multi-year, multi-product programs; accessibility line is building toward a large journals rollout later this year. New lane opened: clients paying MPS to review and quality-check AI-generated instructional content.
Corporate Learning (Liberate Global): Revenue up 6.9% YoY to ₹27.60 crores with EBITDA up 60.7% and margin expanding to 25.3% from under 17%, on a headcount ~33% lighter YoY — last year's restructuring flowing through. Business repositioned from learning creation to enterprise capability enablement: AI-enabled, immersive solutions embedded into LMS, LXP, SharePoint and enterprise platforms. New client additions across geographies; AI-led wins acting as strategic anchors into larger enterprise transformation programs; integration of legacy entities into unified Liberate Global brand ongoing.
Unbound Medicine: First full quarter inside MPS; recurring, high-renewal subscription business anchored in medicine and nursing, selling to medical/nursing schools, hospitals, and academic libraries. Monthly run rate ~$800,000 at 18-20% margins, delivered by a 35-person team on ~$9 million revenue; pricing power evidenced by annual price increases on renewals. Unbound Intelligence — a knowledge-engineering layer converting trusted medical content into non-hallucinating AI products — is a key capability. Early cross-sell conversations with publisher customers started; renewal cycle being learned before synergy timelines are committed.
Company-Specific & Strategic Commentary
AI Strategy: Management's stated principle is "AI should show up in our revenue, not on our slides." DigiCore and Research Integrity Check deployed at scale; AI author workflows have processed well over a million manuscripts; BridgeAI translating at enterprise scale in Corporate Learning. MPS positions itself at "the layer where AI cannot afford to be wrong" — verification, domain context, and the last mile inside real workflows — which management argues is a tailwind as models strengthen, not a threat.
Outcomes-Based Revenue: Revenue is deliberately shifting from payment for effort (pages, hours) to payment for outcomes — manuscripts accepted, paper mills caught, accessible assets delivered at scale, renewable subscriptions, learning programs that change job performance. Management attributes the 20% revenue / 53% EBITDA divergence largely to this mix shift; 25% of revenue is from outcome-based partnerships and 45% from recurring themes.
"Rule of 50": Management's growth-quality test — revenue growth rate plus EBITDA margin — came in at 54 in Q1 (20% + 34.3%). Management is hopeful of clearing 50 for the full year but cautioned against expecting it every quarter due to phasing.
M&A Strategy: Pivot from distressed assets (which distracted management from organic growth) to assets with inherent strength. Filters: revenue >$15 million, Education focus, Science core, high-stakes content where AI is a tailwind (e.g., medical/nursing, cybersecurity); financial filters of 3-year revenue CAGR ≥10% and EBITDA of 5-15%, which MPS raises toward 30%. Financing preference is internal cash accruals (₹15-18 crores/month) plus ~₹200 crores debt capacity; ₹300-500 crore acquisitions seen as doable without equity. Management walked away from an education asset at an advanced stage over cultural and customer-treatment concerns.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY'27 EBITDA | Comfortably cross ₹300 crores | Reaffirmed as a floor, not a target; built bottom-up from each segment's operating plan at an unchanged planning rate; implies ~21% EBITDA CAGR FY'24-FY'27; Q1 landed ahead of a straight-line path and H2 historically outruns H1 |
| FY'28 Targets | ~₹1,500 crores revenue; ~₹450 crores EBITDA | Stated by management in response to analyst question; follows the ₹300 crore FY'27 EBITDA guidance |
| "Rule of 50" | Hopeful of clearing for full FY'27 | Q1 at 54 (20% growth + 34.3% margin); management cautions quarterly phasing will vary |
| Corporate Learning Steady State | ~30% EBITDA margin; ~12% organic growth | Engines: shift to AI-enabled, immersive, performance-focused solutions raising engagement value; account depth via cross-selling, managed learning services, AI platform enablement; multiple enterprise engagements approaching $1 million |
| Unbound Medicine | Rule of 40 first, then Rule of 50 | Currently 18-20% EBITDA margin at ~$800K/month run rate; expected to reach mid-to-late-20s EBITDA margin with balance from revenue growth, then cross Rule of 50 as it integrates |
Risks & Constraints
| Risk | Context |
|---|---|
| Corporate Learning organic growth gap | Segment grew 6.9% YoY against a market management pegs at 12-13% growth; management acknowledged this is "the area where a lot of the catch-up has to happen" and expects MPS to outperform all three end-markets (research ~8-9% market vs MPS ~15%; education ~15% market). |
| AJE reset transition | Consumer base still finding its new level; revenue deliberately smaller but profitable. The pruning is described as behind, with Pre-Submission Peer Review launched and China partnerships signed — but the segment remains a drag on reported growth until the base stabilizes. |
| Acquisition integration and culture | Unbound Medicine is being integrated deliberately — management is learning the renewal cycle before committing to synergy timelines. Management has walked away from deals at advanced stages over cultural misalignment and customer-treatment shortcuts; cultural fit is screened during diligence. |
| AI commoditization perception | Market worry that stronger models commoditize content services; management counters that verification and domain "last mile" become the constraint as models improve, making AI a tailwind. Validated internally by AJE acceptance rates (52% vs 32% industry baseline) and Unbound Intelligence's walled-garden design. |
| Client count decline QoQ | Client count fell from 906 to 841 sequentially; management attributed this entirely to deliberate AJE pruning and confirmed no other rationalisation, but the decline flags ongoing churn in the consumer author segment. |
| M&A funding discipline | Management committed to cash-plus-debt financing (~₹200 crores debt capacity, ₹15-18 crores monthly cash generation) and stated "I don't see an equity play here" — but added "never say never," leaving residual dilution risk on larger deals. |
Q&A Highlights
Management and Culture
- Question: What is driving recent management exits and replacements, and how are you ensuring operational continuity and cultural alignment across geographies post-acquisitions? (Krushi Parekh, BugleRock)
- Answer: MPS is building for 2032 under the Vision 2027/FY'28 framework, and the talent machine is expanding both internally and externally; management is confident decisions are "more often than not" right, with external talent success rates above market and internal promotions up sharply this year. Culture is anchored in core EEE values (excellence, efficiency, empathy), executed through a single ownership-mindset principle that is translated into every acquired asset globally. (Rahul Arora)
Headcount Reduction and Quality Assurance
- Question: Given the reduction in employee base from acquisitions, gig worker usage, and productivity gains, how are you ensuring quality is not diluted? (Krushi Parekh, BugleRock)
- Answer: Corporate Learning headcount is down ~33% YoY in three parts: structural redundancy from restructuring, fixed-to-variable capacity shift toward a gig/associate model, and growing AI productivity — reductions were concentrated in redundant, nonbillable layers, with senior instructional design and client-facing bench untouched; margin expanded without any rise in rework or client escalations. In Research and Education, headcount was roughly stable (2,262→2,452 and 799→765 respectively) as AJE was entirely offshored to India by end of Q4 FY'26; Net Promoter Scores went up during the transition because MPS now has more operational control. (Soma Bhaduri, Rahul Arora)
Client Count Decline
- Question: Client count fell from 906 to 841 QoQ — is there client rationalisation happening? (Kashish Mehta, Dolat Capital)
- Answer: The only pruning in the business is in AJE, as Christine described; no other client rationalisation has taken place. (Rahul Arora)
FY'27/FY'28 Targets and Acquisition Financing
- Question: Earlier you guided ₹300 crores EBITDA for FY'27 against a ₹1,500 crores topline target — has focus shifted from topline to EBITDA, and how will acquisitions be funded without equity dilution? (Ravi Kumar Naredi, Naredi Investment)
- Answer: The ₹1,500 crores revenue target is for FY'28, translating to roughly ₹450 crores EBITDA; FY'27 guidance is to comfortably cross ₹300 crores EBITDA. Acquisition funding: first strike is cash accruals (₹138 crores cash on hand, ₹15-18 crores monthly cash generation); with ~₹200 crores PAT, ~₹200 crores of debt is comfortable — so a ₹300-500 crore acquisition is doable on cash-plus-debt with no equity, though "never say never." An active M&A pipeline targets assets above $15 million revenue in Education and high-stakes content domains where AI is a tailwind (medical/nursing, cybersecurity) — also requiring a motivated seller. (Rahul Arora)
Unbound Medicine — Learnings and Synergies
- Question: Five months into the Unbound acquisition, what new things and challenges have you learned about the sector and company? (Mahesh BP, Individual Investor)
- Answer: New learnings: a Liberate-Unbound synergy around experiential "learning by doing" for nursing and medical education, validated in a U.S. roadshow meeting Unbound customers; Unbound's ownership culture — a 35-person team delivering ~$9 million revenue and growing; and pricing power, with a price increase on every renewal, including 10-year-old customers. The cross-selling opportunity is substantial — AI-enabled immersive and enterprise platform solutions can be layered on top of Unbound's recurring subscription base, and management gained access to senior institutional leaders open to continuous education. (Rahul Arora, Soma Bhaduri)
Unbound Medicine — Run Rate and Margin Trajectory
- Question: What is Unbound's current monthly run rate and margins, and where do you see these in a year or two? (Mahesh BP, Individual Investor)
- Answer: Monthly run rate is ~$800,000 with margins currently in the 18-20% range, increasing from here. The expectation is for Unbound to first climb to Rule of 40 — an EBITDA margin in the mid-to-late 20s with the balance from revenue growth — and ultimately cross Rule of 50 as the business settles into MPS. (Prarthana Agarwal, Rahul Arora)
Corporate Learning Operating Leverage
- Question: Corporate Learning revenue grew ~7% YoY but PBT nearly doubled — is this trajectory sustainable and is there a forex component? (Nachiket Kale, Emkay)
- Answer: The steady state for Corporate Learning is a 30% EBITDA margin with ~12% organic growth; Q1 already shows mix and operating leverage working (revenue +6.9% to ₹27.6 crores, EBITDA +60.7%, margin 16.9%→25.3%). Two engines drive further improvement: AI-enabled, immersive, performance-focused solutions raising engagement value, and deeper existing-account penetration through cross-selling, managed learning services, and AI platform enablement; multiple enterprise engagements are approaching $1 million. Forex: North America is smaller for Corporate Learning than for Research/Education, so the dollar benefit is less pronounced. (Soma Bhaduri, Rahul Arora)
Organic Growth Aspiration and M&A Strategy Evolution
- Question: Ex-Unbound growth is in the early teens — why not much higher organic growth? And how has the M&A strategy changed from smaller to larger acquisitions while preserving culture and fit? (Vikas Mhatre, Moonshot Ventures)
- Answer: Management is not settling: MPS outperforms all three end-markets — research grows 8-9% (MPS ~15%), education is a ~15% growth market (MPS higher), and corporate grows 12-13% (MPS at 6-7%), making corporate the key catch-up area. The old distressed-asset M&A strategy was financially accretive (ROCE north of 30%, sometimes 50%) but distracted the management team from organic growth every year; the pivot is to assets with inherent strength and filters of 3-year revenue CAGR ≥10% and EBITDA of 5-15%, which MPS lifts to ~30%, unlocking Rule of 40. Continuity is managed through team retention with stock options and larger platform roles, and management has walked away from deals at advanced stages over cultural misalignment — including one education asset where the seller had taken shortcuts with customers. (Rahul Arora)
AI Moats by Segment
- Question: With AI advancing rapidly, can you share use cases in each segment where MPS has a real moat that supports superior margins? (Kaushik Jhawar, AK Investment)
- Answer: In Education/Unbound, Unbound Intelligence uses open LLMs scraping a walled garden of peer-reviewed, paywalled content — a nurse querying via mobile app gets answers from sound science, not web opinions, so the chat "cannot get it wrong," unlike generic ChatGPT. In Research, AI is embedded across the production ecosystem and platform stack with AI support for every workflow part from hosting to publishing, compounded by continuous R&D in MPS Labs. In Corporate Learning, MPS acts as an AI transformation partner: modernizing thousands of legacy learning assets on LMS/LXP/SharePoint, deploying chatbots for operational queries, BridgeAI for multilingual experiences, and AI across instructional design, assessment, translation, QA, and media production — while winning enterprise engagements to build AI-enabled learning platforms, Copilots, and simulation-based experiences that raise customer lifetime value and margins. (Rahul Arora, Sukhwant Singh, Soma Bhaduri)
Key Takeaway
MPS Limited delivered its strongest Q1 on record, with revenue up 20.4% YoY to ₹224.24 crores and EBITDA up 53.0% to ₹76.96 crores, as EBITDA margin expanded to 34.3% from 27.0% on headcount growth of under 3% — operating leverage management attributes to AI-enabled delivery and a deliberate shift toward outcomes-based revenue. Research Solutions (55% of revenue) grew 13.2% at a 45.1% segment margin with the Ex-AJE core up 26.3%; Education grew 42.2% on Unbound Medicine's first full quarter (₹800K monthly run rate, 18-20% margins); Corporate Learning expanded margins to 25.3% from 16.9%. Management reaffirmed FY'27 EBITDA guidance to comfortably cross ₹300 crores as a floor, flagged FY'28 targets of ~₹1,500 crores revenue and ~₹450 crores EBITDA, and outlined a cash-plus-debt M&A strategy targeting Education and high-stakes content assets above $15 million in revenue. Watch points include Corporate Learning's organic growth gap (6.9% vs 12-13% market) and the AJE reset's continued drag on reported growth.